Just to hammer down the connection that may exist! How do Electrome, Biel corporation together with DARPA align in terms of vagus nerve research considering also that Biel already has an FDA PEMF device. Although the Biel device is not a Vagus nerve device the FDA does give substantially equivalence to new PMA device applicants.
AI provided the following:
Yes. There is a potentially meaningful scientific and commercial alignment among Electrome, BioElectronics (BIEL), and DARPA's peripheral-neuromodulation work, but there is an important distinction: I do not currently see public evidence establishing that Electrome or BIEL is a DARPA vagus-nerve contractor or that BIEL's ActiPatch is itself a vagus-nerve device. (NDA?)
The more interesting connection is that BIEL's existing FDA-cleared PEMF platform could potentially give Electrome a technology and regulatory foundation from which to investigate more sophisticated bioelectric/neuromodulation applications.
1. The DARPA connection is scientifically quite strong
DARPA's ElectRx (Electrical Prescriptions) program specifically sought technologies capable of treating disease by modulating peripheral nerves, including development of minimally or non-invasive interfaces. DARPA described the objective as targeted stimulation of peripheral nerves, with applications including pain, inflammation, PTSD, anxiety and depression.
The vagus nerve is particularly important because it is a major component of the autonomic nervous system and provides a pathway between the brain and organs. DARPA-supported research has explicitly investigated non-invasive stimulation of nerves in the neck/behind the ear, including the vagus nerve.
So conceptually:
DARPA → peripheral nerve neuromodulation → autonomic nervous system → vagus nerve → bioelectric treatment
That is very close to the broader technological direction that Electrome describes.
2. Where Electrome fits
Electrome currently describes itself as developing "AI-native bioelectric therapeutics" built on FDA-cleared PEMF technology. Its current PainKiller offering uses the FDA-cleared ActiPatch technology.
That is important because Electrome isn't starting with an untested electromagnetic technology.
It potentially has:
BIEL/ActiPatch
→ FDA-cleared PEMF platform
→ Electrome commercialization
→ research into programmable bioelectric stimulation
→ potentially more targeted neuromodulation
→ potentially autonomic/vagus applications
The technological leap would be from:
"Apply electromagnetic energy to reduce pain"
to
"Precisely modulate a particular nerve pathway to produce a desired physiological response."
The latter is much closer to DARPA's bioelectronic-medicine concept.
3. Your FDA point is important — but there is a regulatory correction
This is the part I would modify from your premise.
Substantial equivalence is a 510(k) concept, not a PMA concept.
BIEL's ActiPatch is indeed FDA-cleared through the 510(k) pathway. FDA records show ActiPatch K192234 received a determination of substantial equivalence in January 2020.
And BIEL's earlier ActiPatch K152432 was also cleared through 510(k).
The important FDA distinction is:
Pathway What it means
510(k) Demonstrate substantial equivalence to a legally marketed predicate
De Novo Pathway for certain novel low/moderate-risk devices without an appropriate predicate
PMA More rigorous premarket approval for higher-risk Class III devices
So I would not characterize BIEL as having an "FDA PEMF device that gives substantially equivalent approval to new PMA applicants."
Instead:
BIEL has a 510(k)-cleared PEMF/shortwave therapy device, and that clearance potentially provides useful regulatory precedent for future devices.
That's a significant distinction.
4. But here's where it gets really interesting
BIEL's FDA documentation identifies ActiPatch as a Class II nonthermal shortwave therapy device, product code PQY.
Its original indications were for musculoskeletal pain, including knee osteoarthritis and plantar fasciitis.
The 2020 clearance expanded the indication to musculoskeletal pain generally.
Therefore, BIEL already has FDA-recognized precedent for:
nonthermal pulsed electromagnetic energy → therapeutic effect → human pain treatment
That's valuable.
But it doesn't automatically establish:
PEMF → vagus nerve stimulation → treatment of an autonomic/neurological disease.
That would be a substantially different intended use.
5. Could an Electrome/BIEL vagus device use substantial equivalence?
Possibly—but this is where the regulatory strategy becomes much more complicated.
For a 510(k), FDA asks whether the new device has the same intended use as the predicate and whether technological differences do not raise different questions of safety/effectiveness.
FDA explicitly describes the 510(k) standard in those terms.
The ActiPatch predicate comparison is particularly interesting because BIEL's technology was compared with other pulsed shortwave therapy devices, with similarities in fundamental technology.
But imagine Electrome develops:
ActiPatch-type PEMF
+
specific neck placement
+
specific waveform
+
specific frequency
+
specific pulse pattern
+
targeting of the cervical vagus
+
neurological/autonomic indication
FDA could reasonably conclude that this is not simply another musculoskeletal PEMF device.
That could push the product toward a different regulatory pathway.
6. The strongest opportunity may actually be the technology rather than the predicate
This is where I think your hypothesis becomes particularly interesting.
DARPA's research emphasizes precision, specific nerve targeting, and eventually closed-loop neuromodulation.
A conventional ActiPatch essentially says:
electromagnetic therapy is delivered to an area associated with pain.
A future Electrome technology could potentially say:
electromagnetic stimulation is delivered according to a programmed waveform intended to influence a particular neural pathway.
That's a much more sophisticated bioelectric platform.
And modern bioelectronic medicine increasingly focuses on peripheral nerves as therapeutic targets because they can potentially be modulated with high spatial and temporal specificity.
7. Where I see the three organizations lining up
I'd characterize it this way:
DARPA
Scientific/technology frontier
DARPA has spent years advancing:
peripheral nerve interfaces
bioelectronic medicine
non-invasive neuromodulation
closed-loop stimulation
vagus/peripheral nerve research
electromagnetic and other approaches to neural modulation
BIEL
Existing commercial/regulatory PEMF platform
BIEL brings:
ActiPatch
FDA 510(k) clearance
Class II PEMF/shortwave technology
human clinical experience
manufacturing knowledge
regulatory history
Electrome
Commercialization + next-generation bioelectric platform
Electrome is potentially the bridge between the two:
BIEL's existing PEMF technology
→ Electrome's bioelectric platform
→ more sophisticated neuromodulation
→ potentially autonomic/vagus applications
That is a logical technology-development pathway.
8. One thing I would NOT conclude yet
I would not yet conclude that BIEL + Electrome + DARPA are secretly collaborating on a vagus-nerve product.
I don't find public evidence sufficient to make that claim.
What I do find is a very interesting technology convergence:
DARPA's peripheral nerve/bioelectronic medicine research
⬇
non-invasive neuromodulation
⬇
vagus/autonomic nervous system
⬇
electromagnetic stimulation
⬇
BIEL's existing PEMF platform
⬇
Electrome's new bioelectric/AI commercialization platform
That is a scientifically coherent chain.
9. And the FDA angle could become very important for BIEL shareholders
If Electrome eventually develops a new device using BIEL's underlying PEMF technology, the existing ActiPatch clearance could potentially be useful as part of the regulatory history—but it would not guarantee substantial equivalence.
The really significant development would be evidence that Electrome has developed a new waveform or stimulation protocol that can selectively influence a peripheral/autonomic nerve.
If that happened, BIEL could potentially evolve from being viewed primarily as a pain-therapy PEMF company into being part of a broader bioelectronic-medicine platform.
That would be a much bigger technological story.
My current assessment
Relationship My assessment
BIEL → FDA-cleared PEMF Established
Electrome → BIEL technology Established/publicly represented
DARPA → peripheral nerve neuromodulation Established
DARPA → vagus research Established
PEMF → potential neural modulation Scientifically plausible
ActiPatch → vagus device Not established
BIEL → DARPA collaboration
AI provided the following:
Yes. There is a potentially meaningful scientific and commercial alignment among Electrome, BioElectronics (BIEL), and DARPA's peripheral-neuromodulation work, but there is an important distinction: I do not currently see public evidence establishing that Electrome or BIEL is a DARPA vagus-nerve contractor or that BIEL's ActiPatch is itself a vagus-nerve device. (NDA?)
The more interesting connection is that BIEL's existing FDA-cleared PEMF platform could potentially give Electrome a technology and regulatory foundation from which to investigate more sophisticated bioelectric/neuromodulation applications.
1. The DARPA connection is scientifically quite strong
DARPA's ElectRx (Electrical Prescriptions) program specifically sought technologies capable of treating disease by modulating peripheral nerves, including development of minimally or non-invasive interfaces. DARPA described the objective as targeted stimulation of peripheral nerves, with applications including pain, inflammation, PTSD, anxiety and depression.
The vagus nerve is particularly important because it is a major component of the autonomic nervous system and provides a pathway between the brain and organs. DARPA-supported research has explicitly investigated non-invasive stimulation of nerves in the neck/behind the ear, including the vagus nerve.
So conceptually:
DARPA → peripheral nerve neuromodulation → autonomic nervous system → vagus nerve → bioelectric treatment
That is very close to the broader technological direction that Electrome describes.
2. Where Electrome fits
Electrome currently describes itself as developing "AI-native bioelectric therapeutics" built on FDA-cleared PEMF technology. Its current PainKiller offering uses the FDA-cleared ActiPatch technology.
That is important because Electrome isn't starting with an untested electromagnetic technology.
It potentially has:
BIEL/ActiPatch
→ FDA-cleared PEMF platform
→ Electrome commercialization
→ research into programmable bioelectric stimulation
→ potentially more targeted neuromodulation
→ potentially autonomic/vagus applications
The technological leap would be from:
"Apply electromagnetic energy to reduce pain"
to
"Precisely modulate a particular nerve pathway to produce a desired physiological response."
The latter is much closer to DARPA's bioelectronic-medicine concept.
3. Your FDA point is important — but there is a regulatory correction
This is the part I would modify from your premise.
Substantial equivalence is a 510(k) concept, not a PMA concept.
BIEL's ActiPatch is indeed FDA-cleared through the 510(k) pathway. FDA records show ActiPatch K192234 received a determination of substantial equivalence in January 2020.
And BIEL's earlier ActiPatch K152432 was also cleared through 510(k).
The important FDA distinction is:
Pathway What it means
510(k) Demonstrate substantial equivalence to a legally marketed predicate
De Novo Pathway for certain novel low/moderate-risk devices without an appropriate predicate
PMA More rigorous premarket approval for higher-risk Class III devices
So I would not characterize BIEL as having an "FDA PEMF device that gives substantially equivalent approval to new PMA applicants."
Instead:
BIEL has a 510(k)-cleared PEMF/shortwave therapy device, and that clearance potentially provides useful regulatory precedent for future devices.
That's a significant distinction.
4. But here's where it gets really interesting
BIEL's FDA documentation identifies ActiPatch as a Class II nonthermal shortwave therapy device, product code PQY.
Its original indications were for musculoskeletal pain, including knee osteoarthritis and plantar fasciitis.
The 2020 clearance expanded the indication to musculoskeletal pain generally.
Therefore, BIEL already has FDA-recognized precedent for:
nonthermal pulsed electromagnetic energy → therapeutic effect → human pain treatment
That's valuable.
But it doesn't automatically establish:
PEMF → vagus nerve stimulation → treatment of an autonomic/neurological disease.
That would be a substantially different intended use.
5. Could an Electrome/BIEL vagus device use substantial equivalence?
Possibly—but this is where the regulatory strategy becomes much more complicated.
For a 510(k), FDA asks whether the new device has the same intended use as the predicate and whether technological differences do not raise different questions of safety/effectiveness.
FDA explicitly describes the 510(k) standard in those terms.
The ActiPatch predicate comparison is particularly interesting because BIEL's technology was compared with other pulsed shortwave therapy devices, with similarities in fundamental technology.
But imagine Electrome develops:
ActiPatch-type PEMF
+
specific neck placement
+
specific waveform
+
specific frequency
+
specific pulse pattern
+
targeting of the cervical vagus
+
neurological/autonomic indication
FDA could reasonably conclude that this is not simply another musculoskeletal PEMF device.
That could push the product toward a different regulatory pathway.
6. The strongest opportunity may actually be the technology rather than the predicate
This is where I think your hypothesis becomes particularly interesting.
DARPA's research emphasizes precision, specific nerve targeting, and eventually closed-loop neuromodulation.
A conventional ActiPatch essentially says:
electromagnetic therapy is delivered to an area associated with pain.
A future Electrome technology could potentially say:
electromagnetic stimulation is delivered according to a programmed waveform intended to influence a particular neural pathway.
That's a much more sophisticated bioelectric platform.
And modern bioelectronic medicine increasingly focuses on peripheral nerves as therapeutic targets because they can potentially be modulated with high spatial and temporal specificity.
7. Where I see the three organizations lining up
I'd characterize it this way:
DARPA
Scientific/technology frontier
DARPA has spent years advancing:
peripheral nerve interfaces
bioelectronic medicine
non-invasive neuromodulation
closed-loop stimulation
vagus/peripheral nerve research
electromagnetic and other approaches to neural modulation
BIEL
Existing commercial/regulatory PEMF platform
BIEL brings:
ActiPatch
FDA 510(k) clearance
Class II PEMF/shortwave technology
human clinical experience
manufacturing knowledge
regulatory history
Electrome
Commercialization + next-generation bioelectric platform
Electrome is potentially the bridge between the two:
BIEL's existing PEMF technology
→ Electrome's bioelectric platform
→ more sophisticated neuromodulation
→ potentially autonomic/vagus applications
That is a logical technology-development pathway.
8. One thing I would NOT conclude yet
I would not yet conclude that BIEL + Electrome + DARPA are secretly collaborating on a vagus-nerve product.
I don't find public evidence sufficient to make that claim.
What I do find is a very interesting technology convergence:
DARPA's peripheral nerve/bioelectronic medicine research
⬇
non-invasive neuromodulation
⬇
vagus/autonomic nervous system
⬇
electromagnetic stimulation
⬇
BIEL's existing PEMF platform
⬇
Electrome's new bioelectric/AI commercialization platform
That is a scientifically coherent chain.
9. And the FDA angle could become very important for BIEL shareholders
If Electrome eventually develops a new device using BIEL's underlying PEMF technology, the existing ActiPatch clearance could potentially be useful as part of the regulatory history—but it would not guarantee substantial equivalence.
The really significant development would be evidence that Electrome has developed a new waveform or stimulation protocol that can selectively influence a peripheral/autonomic nerve.
If that happened, BIEL could potentially evolve from being viewed primarily as a pain-therapy PEMF company into being part of a broader bioelectronic-medicine platform.
That would be a much bigger technological story.
My current assessment
Relationship My assessment
BIEL → FDA-cleared PEMF Established
Electrome → BIEL technology Established/publicly represented
DARPA → peripheral nerve neuromodulation Established
DARPA → vagus research Established
PEMF → potential neural modulation Scientifically plausible
ActiPatch → vagus device Not established
BIEL → DARPA collaboration
